{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:28:39Z","timestamp":1789964919751,"version":"4.0.1"},"reference-count":87,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":664,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Clin Exp Hematol"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:p>In this review, we summarize the morphological features and immunophenotypic profile of chronic lymphocytic leukemia (CLL) cells, discuss the value of these investigations as front line diagnostic tests, and emphasize their correlation with the clinical features, disease progression, molecular genetics and pathogenesis of CLL.<\/jats:p><jats:p>In CLL, the morphology of the circulating cells is characteristic and typical in the majority of cases. However, 15% of patients, either at diagnosis or during the course of the disease, show atypical morphology reflected by either <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b1\">(1)<\/jats:ext-link> an increased (&gt;10%) number of circulating prolymphocytes, designated CLL\/PL, or \n\t\t\t\t\t<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b2\">(2)<\/jats:ext-link> an increased (&gt;15%) number of circulating lymphoplasmacytic and cleaved cells, designated \u2018atypical\u2019 CLL. There is strong evidence of a close association between atypical morphology (CLL\/PL) and atypical (CLL) and clinical features, e.g. disease progression, advanced stage and survival, molecular genetics, particularly trisomy 12, but also the rare cases with t(11;14) or t(14;19), p53 abnormalities, unmutated immunoglobulin (Ig) V<jats:sub>H<\/jats:sub> genes and origin of the cell (naive, pregerminal center cell).<\/jats:p><jats:p>CLL cells have a distinct immunological repertoire different from that of other lymphopro\u2010liferative disorders. The typical CLL phenotype is CD5<jats:sup>+<\/jats:sup>, CD23<jats:sup>+<\/jats:sup>, FMC7<jats:sup>\u2013<\/jats:sup>, weak expression of surface Ig (sIg) and weak or absent expression of membrane CD22 and CD79b. The latter marker identifies an extracellular epitope of the B\u2010cell receptor (BCR) <jats:italic>\u03b2<\/jats:italic> chain and its weak or absent expression in CLL may derive from the expression of a truncated form. This, together with the low expression of CD22, might explain the abnormal signal transduction of CLL cells similar to that of anergic B lymphocytes. Because no single marker is specific for CLL, a composite phenotype considering this set of 5 or 6 markers compounded into a scoring system helps to distinguish CLL from the other B\u2010cell malignancies. Immunophenotypic analysis has also been shown to be useful for minimal residual disease detection and adds valuable prognostic information because the expression of certain markers, such as FMC7 or CD38, seems to be associated with a poor outcome.<\/jats:p><jats:p>In addition, CLL cells express a variety of Bcl\u20102 family proteins with a profile that favors inhibition of apoptosis which, together with the interaction with microenvironmental (e.g. stromal) cells and the release of cytokines, explains the long life span and subsequent accumulation of CLL cells in various organs. Despite controversies relating to the expression of adhesion molecules (selectins and integrins) in CLL cells, it appears that some of these molecules do play a role in the pathogenesis, biology and clinical patterns of the disease. In conclusion, morphology and immunophenotype are the two essential investigations, which must be carried out in all cases of CLL. Both provide relevant information in terms of diagnosis, course of the disease, prognosis and pathogenesis.<\/jats:p>","DOI":"10.1046\/j.1468-0734.2000.00002.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T19:08:38Z","timestamp":1047496118000},"page":"22-47","source":"Crossref","is-referenced-by-count":94,"title":["Morphological and Immunophenotypic Features of Chronic Lymphocytic Leukemia"],"prefix":"10.1111","volume":"4","author":[{"given":"Estella","family":"Matutes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Polliack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103398"},{"key":"e_1_2_8_3_2","first-page":"11","volume-title":"Chronic Lymphocytic Leukemia","author":"Linet MS","year":"1988"},{"key":"e_1_2_8_4_2","first-page":"1","article-title":"Cancer incidence and mortality in the USA.","volume":"57","author":"Young JL","year":"1981","journal-title":"NCI Monograph"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(85)90282-6"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood.V91.7.2387","article-title":"CLL B\u2010cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells.","volume":"91","author":"Lagneaux L","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.V87.7.2615.bloodjournal8772615","article-title":"B\u2010chronic lymphocytic leukemia: a malignancy of anti\u2010self B cells.","volume":"87","author":"Caligaris\u2010Cappio F.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409049683"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401153"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.39.24125"},{"key":"e_1_2_8_11_2","first-page":"902","article-title":"Monoclonal antibody Ki\u201067 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity.","volume":"6","author":"Cordone I","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.399"},{"key":"e_1_2_8_13_2","first-page":"88","article-title":"Cytogenetics and molecular genetics of CLL.","volume":"84","author":"Oscier DG.","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_8_14_2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocytic leukemia.","volume":"94","author":"Hamblin TJ","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_15_2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Immunoglobulin V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.","volume":"94","author":"Damle RN","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_16_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia.","volume":"46","author":"Rai KR","year":"1975","journal-title":"Blood"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.42.6.567"},{"key":"e_1_2_8_19_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V55.2.205.205","article-title":"Changes in the Concanavalin A induced redistribution patterns of lymphocytes: a possible aid in the differential diagnosis between malignant lymphoma and other diseases.","volume":"55","author":"Ben Bassat H","year":"1980","journal-title":"Blood"},{"key":"e_1_2_8_20_2","first-page":"213","article-title":"Anomalous function of vimentin in CLL lymphocytes.","volume":"63","author":"Kajden HJ","year":"1984","journal-title":"Blood"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1478.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb03676.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb05563.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.V82.2.571.571","article-title":"Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype and morphology.","volume":"82","author":"Que TH","year":"1993","journal-title":"Blood"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08307.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(96)84956-3"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(96)00247-6"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.2870050210"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05167.x"},{"key":"e_1_2_8_30_2","first-page":"1144","article-title":"Cytogenetic and interphase cytogenetic characterisation of atypical chronic lymphocytic leukemia carrying bcl\u20101 translocation.","volume":"57","author":"Cuneo A","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(95)00152-2"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1505.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3263141.x"},{"key":"e_1_2_8_34_2","first-page":"535a","article-title":"Prognostic significance of membrane antigens and morphology in chronic lymphocytic leukemia.","volume":"94","author":"Matutes E","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_35_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V64.3.642.642","article-title":"Bone marrow histologic pattern \u2013 the best single prognostic parameter in chronic lymphocytic leukemia. A multivariate survival analysis of 329 cases.","volume":"64","author":"Rozman C","year":"1984","journal-title":"Blood"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.450989.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V91.8.2689.2689_2689_2697","article-title":"Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T\u2010cell type costimulatory capacity.","volume":"91","author":"Schattner EJ","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_39_2","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1182\/blood.V88.11.4259.4259","article-title":"Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia.","volume":"88","author":"Safarti M","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(99)90089-8"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.9.1679"},{"key":"e_1_2_8_42_2","first-page":"1640","article-title":"The immunological profile of B\u2010cell disorders and proposal of a scoring system for the diagnosis of CLL.","volume":"8","author":"Matutes E","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_8_43_2","first-page":"1966","article-title":"Expression of the immunoglobulin associated protein B29 in B\u2010cell disorders with the monoclonal antibody SN8 (CD79b).","volume":"10","author":"Zomas AP","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_8_44_2","first-page":"413","article-title":"Quantitative analysis of CD79b, CD5 and CD19 in mature B\u2010cell lymphoproliferative disorders.","volume":"84","author":"Cabezudo E","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_8_45_2","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.V93.7.2327","article-title":"An alternatively spliced form of CD79b gene may account for altered B\u2010cell receptor expression in B\u2010chronic lymphocytic leukemia.","volume":"93","author":"Alfarano A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_46_2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood.V90.4.1387","article-title":"Aberrations of the B\u2010cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia.","volume":"90","author":"Thompson AA","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401561"},{"key":"e_1_2_8_48_2","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.V88.4.1365.bloodjournal8841365","article-title":"CD38 expression distinguishes two groups of B\u2010cell chronic lymphocytic leukemias with different responses to anti\u2010IgM antibodies and pro\u2010pensity to apoptosis.","volume":"88","author":"Zupo S","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_49_2","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1182\/blood.V91.11.4342","article-title":"p53 expression in B\u2010cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.","volume":"91","author":"Cordone I","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4723278.x"},{"key":"e_1_2_8_51_2","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts poor survival and non\u2010response to therapy with purine analogs in chronic B\u2010cell leukemias.","volume":"85","author":"Dohner H","year":"1995","journal-title":"Blood"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.12.5413"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199703)54:3<189::AID-AJH3>3.0.CO;2-S"},{"key":"e_1_2_8_54_2","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.V79.11.2981.2981","article-title":"Growth\u2010 and differentiation\u2010associated ex\u2010pression of bcl\u20102 in B\u2010chronic lymphocytic leukemia cells.","volume":"79","author":"Schena M","year":"1992","journal-title":"Blood"},{"key":"e_1_2_8_55_2","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl\u20102 hypomethylation and high level expression in B\u2010cell chronic lymphocytic leukemia.","volume":"82","author":"Hanada M","year":"1993","journal-title":"Blood"},{"key":"e_1_2_8_56_2","first-page":"456","article-title":"Bcl\u20102 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome.","volume":"10","author":"Robertson LE","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_8_57_2","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.V83.12.3682.3682","article-title":"Bcl\u20102 Translocations leukemias of mature B Cells","volume":"83","author":"Dyer MJS","year":"1994","journal-title":"Blood"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1856.x"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230320"},{"key":"e_1_2_8_60_2","first-page":"1227","article-title":"Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia.","volume":"9","author":"Panayiotidis P","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400582"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(96)00076-8"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1704.x"},{"key":"e_1_2_8_64_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V93.2.624","article-title":"Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion.","volume":"93","author":"Sembries S","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_65_2","first-page":"1088","article-title":"Functional and clinical relevance of CD44 variant isoform expression on B\u2010cell chronic lymphocytic leukemia cells.","volume":"83","author":"Zarcone D","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_8_66_2","first-page":"419","article-title":"Expression of thrombospondin receptor (CD36) in B\u2010cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination.","volume":"84","author":"Rutella S","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050387"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909083394"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00822.x"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00069-6"},{"key":"e_1_2_8_71_2","doi-asserted-by":"crossref","unstructured":"WulfG KludingH HoAD et al.Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and Northern blot analysis.Leuk Res18 475484 1994.","DOI":"10.1016\/0145-2126(94)90085-X"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(93)90041-I"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203978"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609045722"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2090.x"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.6.1750.1750"},{"key":"e_1_2_8_77_2","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1182\/blood.V83.9.2602.2602","article-title":"Surface phenotype and Ig heavy\u2010chain gene usage in chronic B\u2010cell leukemias: expression of myelomonocytic surface markers in CD5\u2013 chronic B\u2010cell leukemia.","volume":"83","author":"Ikematsu W","year":"1994","journal-title":"Blood"},{"issue":"2","key":"e_1_2_8_78_2","first-page":"107","article-title":"Expression of myelomonocytic antigens is associated with unfavourable clinicoprog\u2010nostic factors in B\u2010cell chronic lymphocytic leukaemia.","volume":"2","author":"Pinto A","year":"1991","journal-title":"Ann Oncol"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148515"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.32.533"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(95)00064-X"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01695.x"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(92)90177-9"},{"key":"e_1_2_8_84_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V67.1.80.80","article-title":"Detection of clonal excess in lymphoproliferative diseases by kappa\/lambda analysis: correlation with immunoglobulin gene rearrangement.","volume":"67","author":"Berliner N","year":"1986","journal-title":"Blood"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209053623"},{"key":"e_1_2_8_86_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V80.1.29.29","article-title":"Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisolone: clinical, pathologic, immuno\u2010phenotypic and molecular analysis.","volume":"80","author":"Robertson LE","year":"1992","journal-title":"Blood"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400835"},{"key":"e_1_2_8_88_2","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.V83.6.1558.1558","article-title":"The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B\u2010cell disorders.","volume":"83","author":"Matutes E","year":"1994","journal-title":"Blood"}],"container-title":["Reviews in Clinical and Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-0734.2000.00002.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1468-0734.2000.00002.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1468-0734.2000.00002.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1468-0734.2000.00002.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:55:31Z","timestamp":1694404531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1468-0734.2000.00002.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1046\/j.1468-0734.2000.00002.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1468-0734.2000.00002.x","archive":["Portico"],"relation":{},"ISSN":["1127-0020","1468-0734"],"issn-type":[{"value":"1127-0020","type":"print"},{"value":"1468-0734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}